Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
In the past few years there has been significant progress in the development of therapy for the treatment of relapsing remitting and secondary progressive multiple sclerosis. Research interest in multiple sclerosis (MS) therapeutics has remained high and clinical investigation into potential new therapies continues. This review summarises the advances with currently available therapies and briefly outlines the results from studies with other drugs being developed for the treatment of multiple sclerosis.
Donoghue
S
S
Elan Pharmaceuticals, Elan House, Avenue One, Letchworth, Herts, SG6 2HU, UK.
Greenlees
C
C
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D015507:Drugs, Investigational; D016756:Immunoglobulins, Intravenous; D017338:Cladribine; D016899:Interferon-beta; D008942:Mitoxantrone; D000068556:Interferon beta-1a